BeyondSpring (BYSI) investor relations material

Introduction and purpose

• FDA granted Fast Track designation to plinabulin plus docetaxel for advanced or metastatic non-squamous NSCLC patients who progressed after immune checkpoint inhibitor and platinum-based chemotherapy, targeting those without actionable genomic alterations.

• Fast Track aims to expedite development and review for therapies addressing serious conditions with unmet medical needs, allowing more frequent FDA interaction, potential rolling review, and possible priority review eligibility.

Impact on industry and stakeholders

• The target population in the US and major EU markets could reach 135,000 patients by 2037, representing a substantial commercial opportunity.

• Strategic transaction to sell majority equity in the Chinese subsidiary funds the China portion of the Phase 3 DUBLIN-4 trial, covering about half of the planned 442 global patients and reducing cash requirements.

• This arrangement supports efficient global trial enrollment, especially leveraging China's large eligible patient population.

• BeyondSpring retains global rights to plinabulin outside Greater China.

• Addresses a significant unmet need, as 12 prior phase III studies failed to show OS benefit over docetaxel in this population.

Scientific data and evidence

• Plinabulin is a first-in-class microtubule destabilizer with a unique immunomodulatory mechanism, enhancing dendritic cell maturation and anti-tumor response.

• Over 700 cancer patients have been treated with plinabulin, showing a differentiated immunomodulating mechanism and encouraging results in previous trials.

• DUBLIN-3 phase III showed statistically significant OS benefit for plinabulin plus docetaxel (HR 0.82), with greater benefit in non-squamous patients (HR 0.72), and reduced grade 4 neutropenia.

• Post hoc analysis in post-ICI subgroup: median OS 15.8 vs 11.7 months, PFS 5.6 vs 3.8 months, ORR 18.2% vs 8%.

• Study 303 in post-ICI setting: median PFS 7.0 months, ORR 18%, disease control rate ~80%, two-year OS rate 58%.